Philip Schauer

Philip Schauer led the landmark STAMPEDE trial demonstrating the superiority of metabolic surgery over medical therapy alone for type 2 diabetes, and his subsequent analyses have revealed significant cancer risk reductions in bariatric surgery patients. His long-term outcome studies of metabolic surgery cohorts have provided critical data on sustained weight loss and associated cancer incidence reduction across multiple tumor types. He is a leading voice advocating for metabolic surgery as a cancer prevention strategy in patients with severe obesity.